Compare Gilead Sciences, Inc. (GILD) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Gilead Sciences, Inc. trades at $136.85 (market cap $168.35B), while Norwegian Cruise Line Holdings Ltd trades at $18.92 (market cap $8.59B). The key difference: Gilead Sciences, Inc. is far larger — about 19.6× Norwegian Cruise Line Holdings Ltd's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| GILD | NCLH | |
|---|---|---|
Market Cap | $168.35B | $8.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $26.94 |
52-Week Low | $110.56 | $14.79 |
Enterprise Value | $191.42B | $23.40B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
NCLH trades at $19.09, up 2.91% today, with a bearish technical signal but recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding the $0.4115 estimate, and revenue growth has improved from $4.8B in 2022 to $9.83B in 2025. However, net income margin declined to 4.3% in 2025 from 9.6% in 2024, and high debt levels remain a concern with total liabilities of $18.54B against equity of $1.43B.
The outlook is mixed: analyst consensus is a Buy with a $20.73 price target, but risks include volatile fuel costs, macroeconomic pressures on travel demand, and execution of turnaround plans. The stock offers value with a P/E of 11.33, yet investor sentiment is cautious due to recent guidance cuts and bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
